TransMedics Group, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

TMDX$90.95-3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

Accumulated
Other
Comprehen- · Total
Common Stock · sive Income · Accumulated · Stockholders’
	Shares	Amount	(Loss)	Deficit	Equity
Balances at December 31, 2025	34,267,802	$750,926	$124	$(277,950)	$473,100
Issuance of common stock upon the exercise of common stock options	59,661	2,212	—	—	2,212
Issuance of common stock in connection with employee stock purchase plan	16,321	1,688	—	—	1,688
Net issuance of common stock upon vesting of restricted stock units	201,937	(138)	—	—	(138)
Stock-based compensation expense	—	9,952	—	—	9,952
Foreign currency translation adjustment	—	—	(122)	—	(122)
Net income	—	—	—	7,315	7,315
Balances at March 31, 2026	34,545,721	764,640	2	(270,635)	494,007
Issuance of common stock upon the exercise of common stock options	54,102	1,009	—	—	1,009
Restricted common stock forfeitures	(386)	—	—	—	—
Net issuance of common stock upon vesting of restricted stock units	30,245	(39)	—	—	(39)
Stock-based compensation expense	—	8,606	—	—	8,606
Foreign currency translation adjustment	—	—	(212)	—	(212)
Net income	—	—	—	14,682	14,682
Balances at June 30, 2026	34,629,682	774,216	(210)	(255,953)	518,053
Issuance of common stock upon the exercise of common stock options	36,926	978	—	—	978
Issuance of common stock in connection with employee stock purchase plan	39,794	2,247	—	—	2,247
Net issuance of common stock upon vesting of restricted stock units	16,006	(140)	—	—	(140)
Stock-based compensation expense	—	12,597	—	—	12,597
Foreign currency translation adjustment	—	—	(96)	—	(96)
Net income	—	—	—	17,073	17,073
Balances at September 30, 2026	34,722,408	$789,898	$(306)	$(238,880)	$550,712

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

Accumulated
Other
Comprehen- · Total
Common Stock · sive Income · Accumulated · Stockholders’
	Shares	Amount	(Loss)	Deficit	Equity
Balances at December 31, 2024	33,617,972	$697,208	$(364)	$(468,241)	$228,603
Issuance of common stock upon the exercise of common stock options	77,101	1,742	—	—	1,742
Issuance of common stock in connection with employee stock purchase plan	24,268	1,286	—	—	1,286
Restricted common stock forfeitures	(2,880)	—	—	—	—
Vesting of restricted stock units	111,419	—	—	—	—
Stock-based compensation expense	—	8,958	—	—	8,958
Foreign currency translation adjustment	—	—	37	—	37
Net income	—	—	—	25,682	25,682
Balances at March 31, 2025	33,827,880	709,194	(327)	(442,559)	266,308
Issuance of common stock upon the exercise of common stock options	192,937	7,089	—	—	7,089
Vesting of restricted stock units	18,893	—	—	—	—
Stock-based compensation expense	—	9,372	—	—	9,372
Foreign currency translation adjustment	—	—	425	—	425
Net income	—	—	—	34,907	34,907
Balances at June 30, 2025	34,039,710	725,655	98	(407,652)	318,101
Issuance of common stock upon the exercise of common stock options	55,382	1,816	—	—	1,816
Issuance of common stock in connection with employee stock purchase plan	34,728	1,963	—	—	1,963
Vesting of restricted stock units	15,157	(138)	—	—	(138)
Stock-based compensation expense	—	9,136	—	—	9,136
Foreign currency translation adjustment	—	—	3	—	3
Net income	—	—	—	24,319	24,319
Balances at September 30, 2025	34,144,977	$738,432	$101	$(383,333)	$355,200

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.